Boston's Watchman Under New FDA Scrutiny

BSX's announcement of a third panel meeting for the Watchman device is a small setback, but a setback nonetheless.

Jun 23, 2014 at 5:01PM

"Quis custodiet ipsos custodes" Juvenal, Satires (often translated as "Who watches the watchmen?")

Pipeline development has proved frustratingly difficult for cardiology-focused companies like Medtronic, St. Jude Medical (NYSE:STJ), and Boston Scientific (NYSE:BSX) over the last few quarters. St. Jude modified their clinical trial plans for renal denervation and left atrial appendage closure because of enrollment worries against competing devices from Medtronic and Boston Scientific, while Medtronic's renal denervation program failed a pivotal study and its peripheral drug-coated balloon program has likewise disappointed.

When it comes to Boston Scientific, challenging reimbursement has already gotten in the way of the growth of its Alair bronchial thermoplasty system and now it looks like the Watchman LAA device will be coming to market a year later than expected, if the FDA lets it go to market at all.

Third time's the charm?
A week ago Boston Scientific announced, via a sell-side conference presentation, that the FDA is demanding a third advisory panel meeting on its Watchman left atrial appendage (LAA) closure device) prior to making an approval decision. With no panel meeting on the schedule at present, management shifted its guidance for U.S. approval out by a year – to the first half of 2015.

The first Watchman panel (in April of 2009) resulted in a narrow 7-5 vote in favor of the Watchman "with conditions". The FDA issued a "Not Approvable" letter in March of 2010 and cited problems with the PROTECT AF study (this study showed a 91% implantation success rate and a 38% reduction in endpoint events like stroke).

The company launched the PREVAIL trial in response and while the FDA had issues with this study as well (individual components of the primary endpoint favored the control group), the panel voted 13-1 in favor of Watchman approval in December of 2013.

At this point, it is not publicly know why the FDA is calling for a third panel (and the company may not even know yet). I would suspect that the FDA remains concerned about the risk/benefit of the device and wants further panel guidance and comments on labeling – in particular, which patients should get this device. Short of a flat-out rejection or a demand for yet another new study, the FDA may try to limit the label indication for the device only to those atrial fibrillation patients who are contraindicated for anticoagulant therapy.

This is a case where the specifics do matter. LAA closure devices are not likely to be broadly used in patients who are good candidates for anticoagulants anyway. These medications are not risk-free by any means, but there is a general preference to treat with medications before surgery and the closure devices from St. Jude and Boston Scientific have risks of their own.

A reasonable market, if the devices can get there
The left atrial appendage is a pouch-like structure that is connected to the left atrium of the heart. In healthy people it is believed that the LAA works as a "decompression chamber", but in patients with atrial fibrillation or other conditions it can be a place where blood pools and forms clots. These clots can then move into the brain or other organs and cause significant damage (including stroke).

LAA closure or occlusion is simple enough in principle – it uses a mechanical device-based approach to basically close off that pouch and prevent clots from moving into the heart. Boston Scientific's Watchman and St. Jude's Amplatzer are relatively similar catheter-based devices devices that are implanted through accessing the femoral artery (endovascular). AtriCure's (NASDAQ:ATRC) approach, the AtriClip, is quite a bit different in that it is applied to the outside of the heart as part of a surgical procedure.

Generally speaking, the Boston Scientific and St. Jude endovascular approaches have demonstrated closure rates from the mid-80%'s to the low 90%'s, while AtriCure's AtriClip has delivered closure rates in the high 90%'s. While the higher closure rate of the AtriClip makes it a credible option for patients who need LAA occlusion and are already looking at heart surgery for some other reason, I think it is unlikely to gain more than 25% to 30% share of the market.

Assessing the market potential is tricky, as both the Watchman and Amplatazer are imperfect devices and many physicians view anticoagulation therapy has sufficient.

In any case, most estimates of the LAA closure market call for around $500 million in revenue around 2020. That's not a business-changing opportunity for either Boston Scientific or St. Jude, but it is large enough to be worthwhile, particularly when both companies are looking to new products from their pipeline to stimulate revenue and profit growth.

The bottom line
The good news for Boston Scientific is that the 2014 approval of the Watchman wasn't essential to the company's guidance. It seems pretty clear that the FDA has some real reservations about the Watchman, and it may well prove to be a preview for what's in store for St. Jude as well. Losing the Watchman/Amplatzer LAA would be a modest setback for Boston Scientific and/or St. Jude, though both companies very much need to expand their addressable market and revenue opportunities.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers